ClinicalTrials.gg
RecruitingNCT03125980Updated Apr 24, 2017

Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer

A Phase 3 interventional study of capecitabine plus oxaliplatin before and after surgery and capecitabine plus oxaliplatin after surgery in Locally Advanced Colon Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-24.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2022, 4 years 6 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,370
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Colonic Neoplasms by Fudan University — 11 open to participants now, 12 under way, 3 of them phase 3. Colonic Neoplasms · Fudan University.

Planned enrollment
2nd of 16
1,370 · median 122
Started
2017
the only one that year
Phase 3
3 of 19
3 open now
Primary completion
2022-05
later than 0 of 11 live
Registered
5th of 19
by date

Among the 19 studies in Colonic Neoplasms by Fudan University, this one is the 2nd largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2017, is one of 3 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 5th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

11 of the 19 studies in Colonic Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Colonic Neoplasms by Fudan University, or all of them as a file.
02

Study summary

Adjuvant chemotherapy has been widely adopted worldwide for locally advanced colon cancer. However, more and more studies have found better efficacy and potential advantages of perioperative or neoadjuvant chemotherapy. The sooner the systemic chemotherapy is received, the better suppression it has on activity of tumor growth factors. Pre-operative chemotherapy may eliminate tiny metastases. It may also shrink the invasion of tumor before surgery, and thus reducing operational trauma and expediting recovery. With advances in radiology and tomography, staging before surgery is accurate enough to identify risks and prognosis for patients. The phase II trial conducted by our department has yielded encouraging results (N=47, CapeOX regimen, clinicaltrials.gov NCT02415829): after the neoadjuvant chemotherapy, no subject had disease progression, 68.1% subjects reached complete or partial response. Besides, the toxicity of neoadjuvant CapeOX chemotherapy was acceptable. The present randomized controlled phase III trial will be conducted to further compare efficacy and safety of the neoadjuvant and adjuvant CapeOX chemotherapy for patients with locally advanced resectable colon cancer in China. This study may have two periods, each will last for approximately 5 years. After the first period (n=994), if the results of the test group are better than the control group, the study will be terminated. Otherwise, the study will enter into period 2 (n=376) through selecting out genetically sensitive subjects and repeating the same trial process as period 1.

03

Conditions studied

  • Locally Advanced Colon Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status (PS) ≤ 2;
  • Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: ≥1.5×109/L, count≥100×109/L, ≥80g/L, Serum ≤24umol/L, and aspartate aminotransferase ≤ 60×IU/L, Serum creatinine≤110 umol/L;
  • No current pregnancy or breast-feeding, and subjects at childbearing age shall take method of ;
  • Be in a condition to receive a surgery/procedure;
  • No second tumor at present or in the past 5 years, except skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer;
  • No previous systemic chemotherapy for treating colon cancer;
  • No other chemotherapy at the same time;
  • Expected lifetime longer than three months;
  • Be willing and able to understand the study and to provide written .

Exclusion criteria

Exclusion Criteria:

  • End-stage cachexia patients;
  • Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate CapeOX chemotherapy;
  • carcinoma;
  • Moderate or above anemia caused by serious local tumor bleeding;
  • Incomplete or complete intestinal obstruction;
  • Known to be allergic to oxaliplatin or capecitabine;
  • Active hepatitis, severe coagulation disorder patients;
  • Pregnant or lactating women; or women who have fertility but have not taken at taken adequate measures;
  • Known to have deficient dihydropyrimidine dehydrogenase (DPD);
  • Have vital organ failure or other severe diseases, including but not limited to coronary heart disease, cardiovascular diseases, or myocardial infarction within 12 months before being included; severe neurological or psychiatric history;severe infection; active disseminated intravascular coagulation;
  • Unable or unwilling to abide by the study plan.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,370 participants (estimated)

Study arms

  • Experimental
    Perioperative chemotherapy with CapOX regimen

    Drug: capecitabine plus oxaliplatin before and after surgery

  • Active comparator
    Postoperative chemotherapy with CapOX regimen

    Drug: capecitabine plus oxaliplatin after surgery

Interventions

  • Drugcapecitabine plus oxaliplatin before and after surgery

    Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows: 1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1 2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14 3. Repeat every 3 weeks (Q3W)

  • Drugcapecitabine plus oxaliplatin after surgery

    Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows: 1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1 2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14 3. Q3W

06

What researchers measure

Primary outcomes

  1. 3-year disease free survival

    Defined as the length of time from the date of randomization until the first documented date of progression or death from any cause, whichever comes first

    Time frame: 3 years

Secondary outcomes

  1. R0 resection rate

    Defined as the rate of patients whose tumors are completely resected with all the margins being negative

    Time frame: From the date of randomization until the date of the last patient receiving surgery, assessed up to 40 months

  2. Post-operative TRG staging

    Defined as the TRG staging of tumor after surgery

    Time frame: From the date of randomization until the date of the last patients receiving surgery, assessed up to 40 months

  3. Overall survival (OS)

    Defined as the length of time from randomization date until the date of death from any cause

    Time frame: 5 years

  4. Relapse-free survival (RFS)

    Defined as the length of time from the date of randomization until the first documented date of relapse.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Liu F, Tong T, Huang D, Yuan W, Li D, Lin J, Cai S, Xu Y, Chen W, Sun Y, Zhuang J. CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial. BMJ Open. 2019 Jan 29;9(1):e017637. doi: 10.1136/bmjopen-2017-017637. PubMed 30700474 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2017; primary completion for May 2022, 60 months later.

Of 55 non-industry phase 3 interventional studies under Colonic Neoplasms, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 123. This study's planned 60 months is below that.

Counting every sponsor, half of 72 studies reached it within 55 months; a quarter within 37 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2017
First posted
Apr 24, 2017
StartEst.
May 2017
Primary completionEst.
May 2022
CompletionEst.
May 2027
Last update
Apr 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03125980
Lead sponsor
Fudan University
Responsible party
Sanjun Cai (Professor, Chief physician, Fudan University) — Principal investigator
First posted
Apr 24, 2017
Start date
May 2017 (estimated)
Primary completion
May 2022 (estimated)
Completion
May 2027 (estimated)
Last update
Apr 24, 2017

Study contacts

Sanjun Cai, M.D
Contact
caisanjuncsj@163.com
+86-21-64175590 ext. 81108
Ye Xu, M.D
study director · Department of Colorectal Surgery Fudan University Shanghai Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion